

For immediate release  
08 December 2006



## **Jan van Heek joins PanGenetics' Supervisory Board**

**Utrecht, The Netherlands/ Cambridge UK- 8 December 2006** – PanGenetics B.V. announced today that Jan van Heek will join the company's Supervisory Board. Welcoming Mr. van Heek, Kevin Johnson, CEO of PanGenetics, commented: "I am delighted that Mr. van Heek, who is a senior executive at Genzyme Corporation, has decided to join our team in a supervisory role. His tremendous experience in the biotech industry, combined with his strategic insight will be instrumental in shaping the future path of PanGenetics."

Dr. De Rubertis, Chairman of the Board of PanGenetics, added: "With Mr. van Heek joining as an independent board member, another important step has been taken towards the establishment of PanGenetics as a key player in the field of therapeutic antibodies. I look forward to working with him."

Asked about his reasons for joining the PanGenetics board, Mr. van Heek stated: "I am genuinely impressed by what the PanGenetics team has achieved in a very short time. Within a period of 18 months, they have secured financial backing through a strong and committed investor syndicate, brought together an experienced management team with an impressive track-record and have build a mature portfolio of therapeutic antibodies. Furthermore, I am very attracted by the business model of PanGenetics which is focused on developing in-licensed antibodies through to clinical proof of concept. In my opinion, this model meets the need of the pharmaceutical industry to work with high quality biotech companies to enhance their product portfolios at reduced risk. It will be a great pleasure for me to take on an active role in this exciting company".

The appointment of Mr. van Heek follows two additions to the PanGenetics executive management team earlier this year: Geoff Race, former CEO of Carex, Strasbourg, France, joined the company as Chief Financial Officer and Arnoud Dijkstra joined PanGenetics from Actelion Pharmaceuticals of Switzerland, taking on the responsibility for the company's licensing activities as SVP of Business Development. Kevin Johnson commented: "Geoff's strong background in finance combined with his previous roles as a senior executive in the European biotech industry make him optimally suited to guide the company's financial course. With the addition of Arnoud, we have brought in the necessary business development skills that are required for the execution our business model, which is strongly based on licensing. With both of them on board we have an optimal team in place to take the company forward".

**-ENDS-**

## **Notes for editors**

### **About Jan van Heek**

Jan van Heek joined Genzyme in 1991. From then until April 2004 Mr van Heek was responsible for building the worldwide therapeutics, surgical and genetic testing businesses. He established Genzyme's European offices in the early 90's; and after moving to the US Mr van Heek helped build Genzyme's broad portfolio of businesses and manufacturing infrastructure worldwide. Since April 1, 2004, Mr van Heek's has been employed as a Senior Advisor to the CEO and the senior management team of Genzyme Corporation. In this capacity he has been focused on expansion of business opportunities outside the US. Prior to Genzyme, Mr van Heek held various management positions at Baxter Healthcare Corporation in Europe and the US for over a decade. At Baxter, his last position was as Vice President/General Manager of the Global Fenwal Division of Baxter Healthcare Corporation based in Deerfield, Illinois. Mr van Heek is a board member of Viacell Corporation in Cambridge, MA and Zelos Corporation in Waltham, MA. He received a M.B.A. from St. Gallen University, Switzerland and an executive degree from Stanford Business School, California.

### **About Geoff Race**

Prior to joining PanGenetics, Geoff Race was Chief Executive Officer of CareX SA, a biopharma' specializing in the discovery and development of drugs in the area of metabolic diseases, based in Strasbourg, France. Geoff was responsible for the company's successful merger with 7TM Pharma, a Danish company with a focus in similar disease areas. Prior to joining CareX, Geoff was Chief Executive Officer and Chief Financial Officer of Adprotech Ltd, a 'spin out' of SmithKline Beecham founded in 1997, based near Cambridge, UK which focused on the development of anti-inflammatory products. Before joining Adprotech Ltd, Geoff was Finance Director of Bioprocessing Ltd and participated in the negotiations and the sale of the company to Millipore Corporation in 1999. Geoff's career encompasses several general management roles and Board involvement in 'large' industrial settings as well as 'early stage' companies, including exposure to sectors such as telecommunications and the automotive sector. Geoff is a Fellow of the Chartered Institute of Management Accountants and successfully gained his MBA from Durham University Business School in 1994.

### **About Arnoud Dijkstra**

Before joining PanGenetics as SVP of Business Development in May 2006, Arnoud spent 14 years in the Swiss pharmaceutical and biotech industry. Having received his Ph.D. from the Department of Biophysical Chemistry, Groningen, the Netherlands, Arnoud joined the Pharma Research Department of Hoffmann-La Roche in Basel in 1992, where he spent eight years in several management positions. After this experience in big pharma, he switched to biotech and was involved in setting up the Basel branch of the start-up Morphochem AG, where he served as VP of Operations for three years. He then joined Actelion Pharmaceuticals where, during the two years prior to moving back to Holland, he served as Director of Business Development. In this role he was responsible for all in-licensing search & evaluation programs. In addition he was involved in Actelion's investor relations activities.

### **About PanGenetics B.V.**

PanGenetics is headquartered in Utrecht, The Netherlands with an office near Cambridge in the UK. The company specializes in taking antibodies at the late research stage through to clinical proof of concept. The company employs a lean business model with most development activities outsourced to specialist providers in Europe. The most advanced program is PG102, a CD40 antagonist that has already shown promise in an open label phase Ib/IIa Crohns study. The company's management, board and advisors comprise many of the worlds leading antibody developers.

**Source:** PanGenetics B.V., December 8, 2006

**Contact:** Dr. Arnoud Dijkstra  
Tel. + 31 651 941 921  
[info@PanGenetics.com](mailto:info@PanGenetics.com)  
[www.PanGenetics.com](http://www.PanGenetics.com)

**Northbank Communications:** Sue Charles, Gemma Bradley, Katie Odgaard  
Tel. +44 (0)20 3008 7550  
[pangenetics@northbankcommunications.com](mailto:pangenetics@northbankcommunications.com)